Anthony W. Rowbottom

Dr. Anthony W. Rowbottom

1. Department of Immunology, Royal Preston Hospital, Preston PR2 9HT, UK
+1

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 May 2019 in Scientific Reports
Verified
Journal Article
Open access
PDF file
ECEmma Louise Callery
Emma Louise Callery
CMCamilo L.M. Morais
Camilo L.M. Morais
MPMaria Paraskevaidi
Maria Paraskevaidi
VBVladimir Brusic
Vladimir Brusic
PVPavaladurai Vijayadurai
Pavaladurai Vijayadurai
ARAnthony W. Rowbottom
Anthony W. Rowbottom
Common variable immune deficiency (CVID) is a primary immunodeficiency disease, characterized by hypogammaglobulinemia, recurrent infections and various complications. The clinical heterogeneity of CVID has hindered identification of an underlying immune defect; diagnosis relies on clinical judgement, alongside evidence-based criteria. The lack of pathognomonic clinical or laboratory features leads to average diagnostic delays of 5 years or more from the onset. Vibrational spectroscopic techniques such as Fourier-transform infrared (FTIR) spectroscopy have recently gained increasing clinical importance, being rapid-, non-invasive and inexpensive methods to obtain information on the content of biological samples. This has led us to apply FTIR spectroscopy to the investigation of blood samples from a cohort of CVID patients; revealing spectral features capable of stratifying CVID patients from healthy controls with sensitivities and specificities of 97% and 93%, respectively for serum, and 94% and 95%, respectively for plasma. Furthermore we identified several discriminating spectral biomarkers; wavenumbers in regions indicative of nucleic acids (984 cm−1, 1053 cm−1, 1084 cm−1, 1115 cm−1, 1528 cm−1, 1639 cm−1), and a collagen-associated biomarker (1528 cm−1), which may represent future candidate biomarkers and provide new knowledge on the aetiology of CVID. This proof-of-concept study provides a basis for developing a novel diagnostic tool for CVID.

4 August 2021 in Applied Spectroscopy Reviews
Verified
Journal Article
Closed access
ECEmma Louise Callery
Emma Louise Callery
ARAnthony W. Rowbottom
Anthony W. Rowbottom
Laboratory tests are essential for clinicians to reach an accurate diagnosis and informing appropriate treatments. The expansion in the use of immunotherapies has highlighted the gap between the knowledge of molecular pathways and targeted therapies with availability of laboratory tests. The translation of vibrational spectroscopic techniques such as Fourier-transform infrared (FTIR) spectroscopy and Raman spectroscopy into clinical practice offer rapid-, noninvasive and inexpensive methods to obtain information on the molecular composition of biological samples. Advances in instrumentation, data analysis and machine learning techniques are key developments that have permitted the availability of results to clinicians in an appropriate timescale. Immunological disorders are complex, often demonstrating interaction across multiple molecular pathways which results in delayed diagnosis. Vibrational spectroscopy is being applied in many fields and here we present a review of its potential use in clinical immunology. This review addresses the potential use of spectroscopy in clinical immunology. Potential benefits that these novel techniques offer, including enhanced definition of molecular process and its use in disease diagnosis, monitoring and treatment response is discussed. Whilst not covered extensively, an overview of the method principle, quality control processes, and the requirements for multivariate data analysis is included to provide the reader with sufficient understanding of its application in the clinical setting.

14 December 2022 in Diagnostics
Verified
Journal Article
Open access
PDF file
ECEmma Louise Callery
Emma Louise Callery
CMCamilo L.M. Morais
Camilo L.M. Morais
LNLucy Nugent
Lucy Nugent
ARAnthony W. Rowbottom
Anthony W. Rowbottom
The aim of this study was to explore the proof of concept for using Raman spectroscopy as a diagnostic platform in the setting of systemic lupus erythematosus (SLE). We sought to identify unique Raman signatures in serum blood samples to successfully segregate SLE patients from healthy controls (HC). In addition, a retrospective audit was undertaken to assess the clinical utility of current testing platforms used to detect anti-double stranded DNA (dsDNA) antibodies (n = 600). We examined 234 Raman spectra to investigate key variances between SLE patients (n = 8) and HC (n = 4). Multi-variant analysis and classification model construction was achieved using principal component analysis (PCA), PCA-linear discriminant analysis and partial least squares-discriminant analysis (PLS-DA). We achieved the successful segregation of Raman spectra from SLE patients and healthy controls (p-value < 0.0001). Classification models built using PLS-DA demonstrated outstanding performance characteristics with 99% accuracy, 100% sensitivity and 99% specificity. Twelve statistically significant (p-value < 0.001) wavenumbers were identified as potential diagnostic spectral markers. Molecular assignments related to proteins and DNA demonstrated significant Raman intensity changes between SLE and HC groups. These wavenumbers may serve as future biomarkers and offer further insight into the pathogenesis of SLE. Our audit confirmed previously reported inconsistencies between two key methodologies used to detect anti-dsDNA, highlighting the need for improved laboratory testing for SLE. Raman spectroscopy has demonstrated powerful performance characteristics in this proof-of-concept study, setting the foundations for future translation into the clinical setting.

2 April 2022 in Molecules
Verified
Journal Article
Open access
PDF file
AMAdam Morris
Adam Morris
DFDaniel Lucas Dantas de Freitas
Daniel Lucas Dantas de Freitas
Kássio LimaKássio Lima
Kássio Lima
LFLauren Floyd
Lauren Floyd
MBMark E. Brady
Mark E. Brady
FMFrancis L Martin
Francis L Martin
Biospectroscopy offers the ability to simultaneously identify key biochemical changes in tissue associated with a given pathological state to facilitate biomarker extraction and automated detection of key lesions. Herein, we evaluated the application of machine learning in conjunction with Raman spectroscopy as an innovative low-cost technique for the automated computational detection of disease activity in anti-neutrophil cytoplasmic autoantibody (ANCA)-associated glomerulonephritis (AAGN). Consecutive patients with active AAGN and those in disease remission were recruited from a single UK centre. In those with active disease, renal biopsy samples were collected together with a paired urine sample. Urine samples were collected immediately prior to biopsy. Amongst those in remission at the time of recruitment, archived renal tissue samples representative of biopsies taken during an active disease period were obtained. In total, twenty-eight tissue samples were included in the analysis. Following supervised classification according to recorded histological data, spectral data from unstained tissue samples were able to discriminate disease activity with a high degree of accuracy on blind predictive modelling: F-score 95% for >25% interstitial fibrosis and tubular atrophy (sensitivity 100%, specificity 90%, area under ROC 0.98), 100% for necrotising glomerular lesions (sensitivity 100%, specificity 100%, area under ROC 1) and 100% for interstitial infiltrate (sensitivity 100%, specificity 100%, area under ROC 0.97). Corresponding spectrochemical changes in paired urine samples were limited. Future larger study is required, inclusive of assigned variables according to novel non-invasive biomarkers as well as the application of forward feature extraction algorithms to predict clinical outcomes based on spectral features.

19 April 2017 in Clinical and Experimental Immunology
Verified
Journal Article
Closed access
PDF file
RSR. Saleem
R. Saleem
CKC. Keymer
C. Keymer
DPD. Patel
D. Patel
WEW. Egner
W. Egner
ARAnthony W. Rowbottom
Anthony W. Rowbottom

1 January 2023 in Journal of Spectroscopy
Verified
Journal Article
Open access
PDF file
SKSiddarth Kannan
Siddarth Kannan
ECEmma Louise Callery
Emma Louise Callery
ARAnthony W. Rowbottom
Anthony W. Rowbottom
The investigation of pathological diseases largely relies on laboratory examinations. The ability to identify and characterise cells is an essential process for clinicians to reach an accurate diagnosis and inform appropriate treatments. There is currently a gap between the advancement of scientific knowledge on cellular and molecular pathways and the development of novel techniques capable of detecting subtle cellular changes associated with disease. Biospectroscopy is the use of spectroscopy techniques to investigate biological materials. Within a biological sample, important molecules such as lipids, carbohydrates, nucleic acids, and proteins are held together by chemical bonds; these bonds will vibrate following excitation with infrared light. By measuring the vibrational energy of each molecule present in a biological sample, a unique spectrum, known as the “molecular fingerprint” is generated. As disease‐related changes in biological samples will be reflected in the molecular fingerprint, biospectroscopy is a well‐placed candidate for the investigation of disease. Biospectroscopy has been gaining wider acceptance and application in the clinical setting over the past decade; however, it has yet to reach diagnostic laboratories and healthcare clinics as a routine platform for clinical assessment. Immunological disorders are complex, often demonstrating interaction across multiple molecular pathways which results in delayed diagnosis. Vibrational spectroscopy is being applied in many fields, and here we present a review of its use in cellular immunology. Potential benefits, including an enhanced definition of molecular processes and the use of spectroscopy in disease diagnosis, monitoring, and treatment response, are discussed. The translation of vibrational spectroscopic techniques into clinical practice offers rapid, noninvasive, and inexpensive methods to obtain information on the molecular composition of biological samples. The potential clinical benefits of biospectroscopy include providing a more prompt and accurate disease diagnosis, thus improving patient care and resulting in better health outcomes.